Lilly pharmaceutical confirms to close China R & D center and GSK will gradually close Suzhou plant

Source: Pharmaceutical representative 2017-09-08 this afternoon (September 7), Lilly pharmaceutical closed its China R & D center in Zhangjiang, Shanghai In the evening, the official website of Lilly global officially released a notice to optimize the global business, in which the business measures Department of optimizing drug research and development mentioned that it would close a research and Development Office in Bridgewater, New Jersey, and Lilly China research and development center in Shanghai, China Lilly headquarters announces measures to optimize global operations In the announcement, in addition to the above-mentioned business measures department for optimizing drug research and development, Lilly also announced a voluntary early retirement plan scheme to American employees Employees who meet certain standards can choose to join in and receive additional retirement benefits The scheme is planned to be completed by December 31, 2017; several operating facilities will be closed, and the plan will be located in AI An animal health products factory in Larchwood, Iowa moved to its dodgburg plant in the same state and continues to work to increase productivity globally Mr David A ricks, chairman and CEO of Lilly, said: "Lilly is facing great development opportunities In the past four years, we have launched eight new drugs, and by the end of next year, we may launch two more At present, we are taking necessary actions to optimize operation and reduce fixed costs globally, so as to better seize the opportunity and invest in the next generation of new drug research and development " "Through the measures announced today, Lilly's global business structure will become more streamlined and flexible, which will help accelerate the company's revenue growth, improve operating profit margin and maintain new drug reserves on the product line," Mr Dai added President of Lilly China he ander officially confirmed the news At around 9 p.m., he ander, President of Lilly pharmaceutical China, announced the news to Chinese employees, saying that at the Global CEO connection meeting in the evening, the company announced a series of actions to optimize the company's operation As part of the operation optimization action, Lilly China R & D center in Zhangjiang, Shanghai will be closed At the same time, he ander stressed to employees that Lilly's R & D efforts in China The force will not stop because of this Some employees of the R & D center will join Lilly's drug development and medical affairs department Later, mrclub received a media statement from the head of Lilly media: today, Mr Andrew Hodge, general manager of Lilly China, announced that Lilly pharmaceutical will optimize its business so as to more effectively invest resources in new drug research and development As part of this global initiative, Lilly will close its early clinical research laboratory in Zhangjiang, Shanghai, and focus its R & D activities in China on promoting early and clinical research through more local collaboration and partnerships Lilly will maintain its long-term firm commitment to the Chinese market and continue to retain a considerable local drug R & D team In addition, through the Lilly Asia venture capital fund, we have invested nearly US $1 billion in China so far to help local institutions at the forefront of Chinese pharmaceutical innovation discover and develop new drugs Seven of the companies we invest in are located in Shanghai, and many others are located all over China, including Xinda biopharmaceutical, Sansheng pharmaceutical and Beida pharmaceutical In the future, we will also make full use of China's fast-growing R & D infrastructure to explore new models of cooperation with local companies in drug discovery and early clinical research We will continue to expand and strengthen education and support for diabetics through cooperation with Tencent and dingxiangyuan This series of measures will enable us to promote the development of drugs for the treatment of major diseases and strengthen health education, which will have a positive impact on the lives of millions of Chinese patients Outsourcing strategy has become a global trend for pharmaceutical enterprises The outsourcing of pharmaceutical industry refers to the establishment of a relationship between pharmaceutical companies and external enterprises so that they can undertake some necessary tasks of entering the market The outsourcing phenomenon occurs in the three stages of R & D, production and sales Through outsourcing, pharmaceutical companies can focus on their own core competitiveness, and contract part of their business to external enterprises to make up for their own shortcomings Enough, in this form, most pharmaceutical companies and their partners can achieve profit growth According to relevant statistics, in the 1990s, R & D outsourcing accounted for only 4%, while in the 21st century, almost 42% of the cost of drug R & D process was used for outsourcing Outsourcing is so popular that the number of special enterprises is growing very fast In the early years, according to statistics, in the field of biopharmaceutical industry alone, there were 80 enterprises providing contracted manufacturing outsourcing services for the world, 185 global pharmaceutical or biotechnology companies outsourcing part or all of their pharmaceutical production, including some large pharmaceutical companies, such as Eli Lilly, Pfizer and AstraZeneca Coincidentally, GSK, another multinational pharmaceutical company that closed Zhangjiang central nervous system R & D center at the beginning of last month, also announced the adjustment of China's production and operation, and will gradually close its Suzhou plant For details, please visit another mrclub push on the same day.